Cencora (NYSE:COR) Updates FY25 Earnings Guidance

Cencora (NYSE:COR) issued an update on its FY25 earnings guidance on Wednesday morning. The company provided earnings per share guidance of $14.80-15.10 for the period, compared to the consensus earnings per share estimate of $14.76. The company issued revenue guidance of +7-9% yr/yr to ~$314.6-320.5 billion, compared to the consensus revenue estimate of $312.40 billion. Cencora also updated its FY 2025 guidance to 14.800-15.100 EPS.

Cencora Trading Up 0.3 %

Shares of NYSE:COR traded up $0.65 during midday trading on Friday, reaching $248.41. 1,362,376 shares of the company’s stock were exchanged, compared to its average volume of 1,409,791. The firm’s 50 day simple moving average is $231.77 and its two-hundred day simple moving average is $230.76. The company has a debt-to-equity ratio of 3.93, a current ratio of 0.89 and a quick ratio of 0.55. The stock has a market cap of $48.95 billion, a price-to-earnings ratio of 32.99, a P/E/G ratio of 1.49 and a beta of 0.44. Cencora has a fifty-two week low of $191.11 and a fifty-two week high of $251.00.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, November 6th. The company reported $3.34 earnings per share for the quarter, topping the consensus estimate of $3.21 by $0.13. Cencora had a net margin of 0.65% and a return on equity of 266.60%. The company had revenue of $79.05 billion during the quarter, compared to analyst estimates of $77.68 billion. As a group, sell-side analysts forecast that Cencora will post 13.64 EPS for the current fiscal year.

Cencora Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, November 29th. Investors of record on Friday, November 15th will be issued a $0.55 dividend. This represents a $2.20 annualized dividend and a yield of 0.89%. The ex-dividend date of this dividend is Friday, November 15th. This is an increase from Cencora’s previous quarterly dividend of $0.51. Cencora’s dividend payout ratio (DPR) is 29.29%.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. JPMorgan Chase & Co. raised their price target on Cencora from $280.00 to $287.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 21st. Robert W. Baird raised their target price on Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a report on Thursday. Evercore ISI boosted their price target on shares of Cencora from $250.00 to $285.00 and gave the stock an “outperform” rating in a research note on Thursday. Wells Fargo & Company raised their price objective on shares of Cencora from $236.00 to $249.00 and gave the company an “equal weight” rating in a research note on Thursday, August 1st. Finally, Bank of America reaffirmed a “neutral” rating and set a $245.00 target price (down from $275.00) on shares of Cencora in a research note on Wednesday, September 18th. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $271.20.

Insiders Place Their Bets

In other news, Chairman Steven H. Collis sold 21,509 shares of the firm’s stock in a transaction on Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total value of $5,071,822.20. Following the sale, the chairman now directly owns 285,088 shares in the company, valued at approximately $67,223,750.40. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 15.80% of the stock is currently owned by company insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.